People in the UK under 30 will be offered an alternative to the AstraZeneca vaccine because of a possible link to rare blood clots. Could the move dent confidence in the widely used jab?
The government’s Joint Committee on Vaccines and Immunisation said this week that people aged 18 to 29 who are not at high risk of Covid should have the option of an alternative jab to the AstraZeneca vaccine if one is available in their area. It follows the accumulation of evidence linking the jab to rare blood clots, although no definitive causation has yet been established. The move has sparked fears of a loss of confidence in the widely used AstraZeneca vaccine, at a point when the UK is emerging from lockdown.
The Observer’s science editor, Robin McKie, tells Anushka Asthana that the risks of blood clots are still incredibly low: the current evidence puts the risk at about one in every 250,000 shots. But given there are other vaccines to offer, he says this caution makes sense.
